BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $407.07

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $412.26.

ONC has been the topic of several recent research reports. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Morgan Stanley reissued an “overweight” rating and set a $425.00 target price on shares of BeOne Medicines in a report on Friday, October 16th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Citizens Jmp boosted their target price on shares of BeOne Medicines from $396.00 to $405.00 and gave the company a “market outperform” rating in a research report on Thursday, August 6th. Finally, Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th.

Insider Buying and Selling

In other news, SVP Chan Lee sold 2,666 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $360.00, for a total value of $959,760.00. Following the completion of the transaction, the senior vice president owned 812 shares of the company’s stock, valued at $292,320. The trade was a 76.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 115,011 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the completion of the sale, the chief executive officer owned 125,799 shares in the company, valued at $45,019,688.13. The trade was a 47.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 376,373 shares of company stock worth $134,848,154. Corporate insiders own 6.19% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ONC. Mather Group LLC. lifted its holdings in BeOne Medicines by 192.0% in the third quarter. Mather Group LLC. now owns 73 shares of the company’s stock valued at $27,000 after acquiring an additional 48 shares during the period. GAMMA Investing LLC grew its stake in shares of BeOne Medicines by 39.5% during the 3rd quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock worth $44,000 after purchasing an additional 34 shares during the period. Parallel Advisors LLC grew its stake in shares of BeOne Medicines by 24.0% during the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock worth $104,000 after purchasing an additional 68 shares during the period. Provenance Wealth Advisors LLC purchased a new position in shares of BeOne Medicines during the 3rd quarter valued at approximately $106,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of BeOne Medicines by 16.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after purchasing an additional 52 shares in the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Stock Performance

Shares of NASDAQ:ONC opened at $370.33 on Monday. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $388.66. The stock has a market cap of $40.66 billion, a price-to-earnings ratio of 65.20 and a beta of 0.63. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average price of $363.15 and a 200-day moving average price of $325.44.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. Equities analysts predict that BeOne Medicines will post 8.99 EPS for the current year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.